Developer docs
API playgroundTry for free, no card

Search company profiles

DyDo Pharma

Full company profile

uuid0023dhu

Namestring
DyDo Pharma
Legal namestring
ダイドーファーマ株式会社
Company typeenum
Private
Founded yearint
2019
Descriptiontext

DyDo Pharma Co., Ltd. (ダイドーファーマ株式会社) is a privately held Japanese specialty pharmaceutical company founded in March 2019 in Osaka as a wholly-owned subsidiary of DyDo Group Holdings Co., Ltd. The company is focused exclusively on developing and commercializing treatments for rare diseases, with its single therapeutic focus being Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare autoimmune neuromuscular disorder with a reported Japanese prevalence of 0.27 per 100,000.

The company's core product is FIRDAPSE® Tablets 10mg, an oral formulation of amifampridine phosphate — a voltage-gated potassium (K+) channel blocker that extends depolarization at the presynaptic terminal of the neuromuscular junction, increasing acetylcholine release and improving muscle weakness in LEMS patients. The drug was in-licensed from Catalyst Pharmaceuticals under an exclusive Japanese development and commercialization agreement signed in June 2021, validated through a Japanese Phase III trial (LMS-005), and received Japanese manufacturing and marketing approval on September 24, 2024. It was commercially launched in Japan on January 21, 2025, as the first oral treatment approved in Japan for LEMS, and holds Japanese orphan (R3) drug designation (#515, May 2021).

DyDo Pharma's business model is a classic specialty/orphan pharmaceutical model: it sells a single, NHI-priced prescription drug through licensed pharmaceutical wholesalers to hospitals and specialist clinics, primarily targeting neurologists and neuroimmunologists. The company supports uptake through medical representative field activities, sponsorship of Japanese neurology and neuroimmunology societies, and dedicated disease-information websites for healthcare professionals and patients. Revenue is generated from prescription drug sales at NHI-regulated prices, and the company has built supporting infrastructure including a dedicated logistics center opened in October 2024.

Short descriptiontext

DyDo Pharma is a Japanese specialty pharmaceutical subsidiary of DyDo Group Holdings that develops and commercializes FIRDAPSE® Tablets 10mg, the first oral treatment approved in Japan for the rare autoimmune neuromuscular disorder Lambert-Eaton myasthenic syndrome (LEMS).

Operating statusenum
Operating
Ownership categoryenum
akta.pro rankint
HeadquartersOsaka, Japan
HQ citystring
Osaka
HQ countrystring
Japan
HQ regionstring
Asia
Markets served

Serves global market

Keyword5 values
rare disease therapeutics, neuromuscular disorder treatment, potassium channel blockers, orphan drug development, prescription pharmaceuticals
NAICS code1 code
  • Research and Development in Biotechnology (except Nanobiotechnology)541714
SIC code1 code
  • Pharmaceutical Preparations2834
Product category
Specialty Pharmaceuticals (Rare Disease Therapeutics)
No data
Marketing channels4 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels1 record

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 record
1FIRDAPSE® Tablets 10mg (ファダプス®錠10mg)
Description

Lambert-Eaton myasthenic syndrome (LEMS) treatment drug containing amifampridine phosphate (3,4-diaminopyridine). It is Japan's first oral treatment for LEMS.

medical.dydopharma.co.jp
Core offering1 text field

DyDo Pharma develops, manufactures, and commercializes FIRDAPSE® Tablets 10mg (amifampridine phosphate), Japan's first approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS). The drug is a voltage-gated potassium channel blocker that improves neuromuscular transmission by extending depolarization at the presynaptic terminal and promoting acetylcholine release. The company also supports prescribers and patients via dedicated disease-information websites.

Differentiator
Functional benefit
Problem solved
Product overview1 text field

DyDo Pharma is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, specifically Lambert-Eaton myasthenic syndrome (LEMS). The company's main product is FIRDAPSE® Tablets 10mg (amifampridine phosphate), the first oral treatment approved in Japan for LEMS. The company operates dedicated disease information platforms for both medical professionals and patients/general public to support awareness and proper diagnosis of LEMS.

Product and service1 record
1FIRDAPSE® Tablets 10mg (ファダプス®錠10mg)
CategorySpecialty Prescription Pharmaceutical (Rare Disease Therapeutic)
Description

FIRDAPSE® Tablets 10mg is an oral prescription pharmaceutical containing amifampridine phosphate (10mg per tablet) used for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adult patients. It is a voltage-gated potassium channel blocker that extends the depolarization time at the presynaptic terminal of the neuromuscular junction, promoting acetylcholine release to enhance neuromuscular transmission and improve muscle weakness. It is Japan's first approved oral treatment for LEMS and is prescribed by neurologists.

Partnership1 partner
Strategic tierCoreTypeOEM/ Whitelabel/ Licensing PartnerAnnounced on2021-06-28
Description

DyDo Pharma acquired exclusive rights from Catalyst Pharmaceuticals to develop and commercialize amifampridine phosphate (FIRDAPSE®) for the Japanese market. The licensing agreement covers LEMS indication. The drug was subsequently developed through Japanese Phase III clinical trials (LMS-005), received approval in Japan in September 2024, and was commercially launched in January 2025.

Recent move7 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight4 records

Each record includes

Type, Description

Peers10 records
TypeEmerging player
Description

A Belgium-based biotech focused on severe autoimmune diseases including myasthenia gravis (a related neuromuscular autoimmune disorder). Comparable in neuromuscular autoimmune disease focus and orphan-drug commercial model.

TypeBroad incumbent
Description

A larger US rare-disease biopharma with a portfolio of orphan drugs for small patient populations. Comparable in business model of focusing on rare diseases with premium pricing and orphan drug protections.

TypeDirect peer
Description

Catalyst Pharmaceuticals developed and commercializes FIRDAPSE® (amifampridine) for LEMS in the US — DyDo Pharma's licensor and the originator of the asset DyDo is commercializing in Japan, making it the most directly comparable commercial peer.

TypeBroad incumbent
Description

A commercial-stage rare-disease biotech developing and commercializing therapies for rare and ultra-rare genetic diseases. Comparable in targeting small patient populations via orphan-drug commercialization.

TypeBroad incumbent
Description

Japan's largest pharma company with a substantial rare-disease franchise (post-Shire acquisition). Comparable as a Japan-based rare-disease commercial player, though at vastly greater scale.

TypeBroad incumbent
Description

UCB develops and markets therapies for rare neurological and immunological conditions including myasthenia gravis. Comparable as a large pharma with neuromuscular rare-disease commercial operations.

TypeBroad incumbent
Description

Sanofi's Genzyme unit is a global leader in rare diseases (including rare neurological disorders). Comparable as an established rare-disease commercial operation with orphan-drug expertise and global reach.

TypeRegional player
Description

Japan Tobacco's pharmaceutical division focuses on rare and intractable diseases, including products overlapping with neurology/autoimmune indications. Comparable as a Japanese pharma with a rare-disease focus.

TypeDirect peer
Description

Recordati's rare disease business commercializes treatments for rare conditions including LEMS in Europe. Closely comparable to DyDo Pharma as a rare-disease-focused commercial entity with global reach.

TypeBroad incumbent
Description

Alexion pioneered the rare-disease commercial model with Soliris/Ultomiris for rare complement-mediated disorders. Highly comparable as the gold-standard rare-disease commercial organization.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat4 records

Each record includes

Type, Details

Key risks5 records

Each record includes

Headline, Details, Source

Key highlights6 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Segment1 record

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile1 record

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

Technology focused
No
API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature1 record

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
Profiles1 record

Each record includes

Name, Designation, Designation category, Overview, Profile commentary, Source

No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

DyDo Pharma

Specialty Pharmaceuticals (Rare Disease Therapeutics)dydopharma.co.jp

DyDo Pharma is a Japanese specialty pharmaceutical subsidiary of DyDo Group Holdings that develops and commercializes FIRDAPSE® Tablets 10mg, the first oral treatment approved in Japan for the rare autoimmune neuromuscular disorder Lambert-Eaton myasthenic syndrome (LEMS).

What DyDo Pharma does

DyDo Pharma Co., Ltd. (ダイドーファーマ株式会社) is a privately held Japanese specialty pharmaceutical company founded in March 2019 in Osaka as a wholly-owned subsidiary of DyDo Group Holdings Co., Ltd. The company is focused exclusively on developing and commercializing treatments for rare diseases, with its single therapeutic focus being Lambert-Eaton myasthenic syndrome (LEMS), an ultra-rare autoimmune neuromuscular disorder with a reported Japanese prevalence of 0.27 per 100,000.

The company's core product is FIRDAPSE® Tablets 10mg, an oral formulation of amifampridine phosphate — a voltage-gated potassium (K+) channel blocker that extends depolarization at the presynaptic terminal of the neuromuscular junction, increasing acetylcholine release and improving muscle weakness in LEMS patients. The drug was in-licensed from Catalyst Pharmaceuticals under an exclusive Japanese development and commercialization agreement signed in June 2021, validated through a Japanese Phase III trial (LMS-005), and received Japanese manufacturing and marketing approval on September 24, 2024. It was commercially launched in Japan on January 21, 2025, as the first oral treatment approved in Japan for LEMS, and holds Japanese orphan (R3) drug designation (#515, May 2021).

DyDo Pharma's business model is a classic specialty/orphan pharmaceutical model: it sells a single, NHI-priced prescription drug through licensed pharmaceutical wholesalers to hospitals and specialist clinics, primarily targeting neurologists and neuroimmunologists. The company supports uptake through medical representative field activities, sponsorship of Japanese neurology and neuroimmunology societies, and dedicated disease-information websites for healthcare professionals and patients. Revenue is generated from prescription drug sales at NHI-regulated prices, and the company has built supporting infrastructure including a dedicated logistics center opened in October 2024.

DyDo Pharma firmographics

Firmographics
Name
DyDo Pharma
Legal name
ダイドーファーマ株式会社
Website
https://dydopharma.co.jp
Company type
Private
Founded year
2019
Operating status
Operating
Short description
DyDo Pharma is a Japanese specialty pharmaceutical subsidiary of DyDo Group Holdings that develops and commercializes FIRDAPSE® Tablets 10mg, the first oral treatment approved in Japan for the rare autoimmune neuromuscular disorder Lambert-Eaton myasthenic syndrome (LEMS).
Ownership category
akta.pro rank

Where DyDo Pharma is headquartered

Location

Headquarters

HQ city
Osaka
HQ country
Japan
HQ region
Asia

Markets served

DyDo Pharma business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Personnel, Operations, Marketing or Sales, Technology or R&D, Supply Chain

Distribution channels1 record

Marketing channels4 records

DyDo Pharma product offering

Product offering

Core offering

DyDo Pharma develops, manufactures, and commercializes FIRDAPSE® Tablets 10mg (amifampridine phosphate), Japan's first approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS). The drug is a voltage-gated potassium channel blocker that improves neuromuscular transmission by extending depolarization at the presynaptic terminal and promoting acetylcholine release. The company also supports prescribers and patients via dedicated disease-information websites.

Product overview

DyDo Pharma is a pharmaceutical company focused on developing and commercializing treatments for rare diseases, specifically Lambert-Eaton myasthenic syndrome (LEMS). The company's main product is FIRDAPSE® Tablets 10mg (amifampridine phosphate), the first oral treatment approved in Japan for LEMS. The company operates dedicated disease information platforms for both medical professionals and patients/general public to support awareness and proper diagnosis of LEMS.

Differentiator

Problem solved

Functional benefit

Brands

  • FIRDAPSE® Tablets 10mg (ファダプス®錠10mg): Lambert-Eaton myasthenic syndrome (LEMS) treatment drug containing amifampridine phosphate (3,4-diaminopyridine). It is Japan's first oral treatment for LEMS.

Products and services

  • FIRDAPSE® Tablets 10mg (ファダプス®錠10mg) FIRDAPSE® Tablets 10mg is an oral prescription pharmaceutical containing amifampridine phosphate (10mg per tablet) used for the treatment of Lambert-Eaton myasthenic syndrome (LEMS) in adult patients. It is a voltage-gated potassium channel blocker that extends the depolarization time at the presynaptic terminal of the neuromuscular junction, promoting acetylcholine release to enhance neuromuscular transmission and improve muscle weakness. It is Japan's first approved oral treatment for LEMS and is prescribed by neurologists.

Companies that use DyDo Pharma

Customer profile

Segments1 record

Ideal customer profiles1 record

DyDo Pharma technology and API

Technology

Technology focussed No

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature1 record

DyDo Pharma partnerships and signals

Strategic signal

Partnerships

One partnership is on record.

  • Catalyst Pharmaceuticals (Catalyst Biosciences at time of original deal)coreOEM/ Whitelabel/ Licensing Partner · 28 June 2021DyDo Pharma acquired exclusive rights from Catalyst Pharmaceuticals to develop and commercialize amifampridine phosphate (FIRDAPSE®) for the Japanese market. The licensing agreement covers LEMS indication. The drug was subsequently developed through Japanese Phase III clinical trials (LMS-005), received approval in Japan in September 2024, and was commercially launched in January 2025.

Recent moves7 records

Expansion highlights4 records

DyDo Pharma competitors and assessment

Company assessment

Emerging players

  • argenx: A Belgium-based biotech focused on severe autoimmune diseases including myasthenia gravis (a related neuromuscular autoimmune disorder). Comparable in neuromuscular autoimmune disease focus and orphan-drug commercial model.

Broad incumbents

  • BioMarin Pharmaceutical: A larger US rare-disease biopharma with a portfolio of orphan drugs for small patient populations. Comparable in business model of focusing on rare diseases with premium pricing and orphan drug protections.
  • Ultragenyx Pharmaceutical: A commercial-stage rare-disease biotech developing and commercializing therapies for rare and ultra-rare genetic diseases. Comparable in targeting small patient populations via orphan-drug commercialization.
  • Takeda Pharmaceutical (Rare Diseases): Japan's largest pharma company with a substantial rare-disease franchise (post-Shire acquisition). Comparable as a Japan-based rare-disease commercial player, though at vastly greater scale.
  • UCB (Rare Disease portfolio): UCB develops and markets therapies for rare neurological and immunological conditions including myasthenia gravis. Comparable as a large pharma with neuromuscular rare-disease commercial operations.
  • Sanofi Genzyme (Rare Disease): Sanofi's Genzyme unit is a global leader in rare diseases (including rare neurological disorders). Comparable as an established rare-disease commercial operation with orphan-drug expertise and global reach.
  • Alexion / AstraZeneca Rare Disease: Alexion pioneered the rare-disease commercial model with Soliris/Ultomiris for rare complement-mediated disorders. Highly comparable as the gold-standard rare-disease commercial organization.

Direct peers

  • Catalyst Pharmaceuticals: Catalyst Pharmaceuticals developed and commercializes FIRDAPSE® (amifampridine) for LEMS in the US — DyDo Pharma's licensor and the originator of the asset DyDo is commercializing in Japan, making it the most directly comparable commercial peer.
  • Recordati Rare Diseases: Recordati's rare disease business commercializes treatments for rare conditions including LEMS in Europe. Closely comparable to DyDo Pharma as a rare-disease-focused commercial entity with global reach.

Regional players

  • Japan Tobacco Inc. (Pharmaceutical Division): Japan Tobacco's pharmaceutical division focuses on rare and intractable diseases, including products overlapping with neurology/autoimmune indications. Comparable as a Japanese pharma with a rare-disease focus.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat4 records

Key risks5 records

Key highlights6 records

Customer concentration

DyDo Pharma financial estimates

Financial estimate

Revenue estimate

Valuation estimate

DyDo Pharma leadership team

Management profile

Number of profiles

Profiles1 record

DyDo Pharma funding detail

Funding detail

Funding overview

Funding rounds

Investors

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

DyDo Pharma M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about DyDo Pharma

What does DyDo Pharma do?

DyDo Pharma develops, manufactures, and commercializes FIRDAPSE® Tablets 10mg (amifampridine phosphate), Japan's first approved oral treatment for Lambert-Eaton myasthenic syndrome (LEMS). The drug is a voltage-gated potassium channel blocker that improves neuromuscular transmission by extending depolarization at the presynaptic terminal and promoting acetylcholine release. The company also supports prescribers and patients via dedicated disease-information websites.

Is DyDo Pharma a public or private company?

DyDo Pharma is a private company. It is classified as corporate owned and is currently operating.

When was DyDo Pharma founded?

DyDo Pharma was founded in 2019.

Where is DyDo Pharma based?

DyDo Pharma is headquartered in Osaka, Japan, in the Asia region.

Who are DyDo Pharma's main competitors?

argenx is listed as an emerging player. Broad incumbents are BioMarin Pharmaceutical, Ultragenyx Pharmaceutical, Takeda Pharmaceutical (Rare Diseases), UCB (Rare Disease portfolio), Sanofi Genzyme (Rare Disease) and Alexion / AstraZeneca Rare Disease. Direct peers are Catalyst Pharmaceuticals and Recordati Rare Diseases. Japan Tobacco Inc. (Pharmaceutical Division) is listed as a regional player.

Does DyDo Pharma have an API?

No public API is recorded for DyDo Pharma.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals